Loading…
A four‐gene signature associated with clinical features can better predict prognosis in prostate cancer
Prostate cancer (PCa) is one of the most deadly urinary tumors in men globally, and the 5‐year over survival is poor due to metastasis of tumor. It is significant to explore potential biomarkers for early diagnosis and personalized therapy of PCa. In the present study, we performed an integrated ana...
Saved in:
Published in: | Cancer medicine (Malden, MA) MA), 2020-11, Vol.9 (21), p.8202-8215 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5093-5ef8495c14f52c0090b4daa8a6a1cacbc9cbda33a2179503ab76ced8f3bca8e23 |
---|---|
cites | cdi_FETCH-LOGICAL-c5093-5ef8495c14f52c0090b4daa8a6a1cacbc9cbda33a2179503ab76ced8f3bca8e23 |
container_end_page | 8215 |
container_issue | 21 |
container_start_page | 8202 |
container_title | Cancer medicine (Malden, MA) |
container_volume | 9 |
creator | Yuan, Penghui Ling, Le Fan, Qing Gao, Xintao Sun, Taotao Miao, Jianping Yuan, Xianglin Liu, Jihong Liu, Bo |
description | Prostate cancer (PCa) is one of the most deadly urinary tumors in men globally, and the 5‐year over survival is poor due to metastasis of tumor. It is significant to explore potential biomarkers for early diagnosis and personalized therapy of PCa. In the present study, we performed an integrated analysis based on multiple microarrays in the Gene Expression Omnibus (GEO) dataset and obtained differentially expressed genes (DEGs) between 510 PCa and 259 benign issues. The weighted correlation network analysis indicated that prognostic profile was the most relevant to DEGs. Then, univariate and multivariate COX regression analyses were conducted and four prognostic genes were obtained to establish a four‐gene prognostic model. And the predictive effect and expression profiles of the four genes were well validated in another GEO dataset, The Cancer Genome Atlas and the Human Protein Atlas datasets. Furthermore, combination of four‐gene model and clinical features was analyzed systematically to guide the prognosis of patients with PCa to a largest extent. In summary, our findings indicate that four genes had important prognostic significance in PCa and combination of four‐gene model and clinical features could achieve a better prediction to guide the prognosis of patients with PCa.
Prostate cancer (PCa) is one of the most deadly urinary tumors in men globally, and the progression and development of PCa is associated with copious genetic aberrations. This study is aimed to add novel biomarkers of PCa development and prognosis by analyzing the genetic changes and clinical traits comprehensively. Based on integrated analysis, four genes were significantly related to the prognosis of PCa and well validated in other datasets. Furthermore, combination of four genes and clinical features achieved a better prediction to guide the prognosis of patients with PCa. |
doi_str_mv | 10.1002/cam4.3453 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_90a7bd7c88fc4847a53452168ebadea6</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_90a7bd7c88fc4847a53452168ebadea6</doaj_id><sourcerecordid>2442596585</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5093-5ef8495c14f52c0090b4daa8a6a1cacbc9cbda33a2179503ab76ced8f3bca8e23</originalsourceid><addsrcrecordid>eNp1ks1q3DAQgE1paUKaQ1-gCHppD5vo3_KlsCz9CaT00p7FeDx2tHjtreRtyK2PkGfMk1TeTUNSqA4a_Xx8DDNTFK8FPxOcy3OEjT5T2qhnxbHk2ixKq_TzR-ej4jSlNc-r5NKW4mVxpGQldd6Oi7Bk7biLd79vOxqIpdANMO0iMUhpxAATNew6TFcM-zAEhJ61tAcSQxhYTdNEkW0jNQGnHMduGFNILAzzJU1ZMINI8VXxooU-0el9PCl-fPr4ffVlcfnt88VqeblAwyu1MNQ6XRkUujUSOa94rRsABxYEAtZYYd2AUiBFWRmuoC4tUuNaVSM4kuqkuDh4mxHWfhvDBuKNHyH4_cMYOw9xCtiTrziUdVOicy1qp0swuY5SWEc1NAQ2uz4cXNtdvaEGaZgi9E-kT3-GcOW78ZcvrVZWz8m8uxfE8eeO0uQ3ISH1PQw07pKXWktTWeNMRt_-g65zY4ZcqkyZ0thKOJGp9wcKc3VTpPYhGcH9PA9-ngc_z0Nm3zzO_oH82_0MnB-A69DTzf9NfrX8qvfKP8JOwk4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2457569181</pqid></control><display><type>article</type><title>A four‐gene signature associated with clinical features can better predict prognosis in prostate cancer</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>Wiley Open Access</source><creator>Yuan, Penghui ; Ling, Le ; Fan, Qing ; Gao, Xintao ; Sun, Taotao ; Miao, Jianping ; Yuan, Xianglin ; Liu, Jihong ; Liu, Bo</creator><creatorcontrib>Yuan, Penghui ; Ling, Le ; Fan, Qing ; Gao, Xintao ; Sun, Taotao ; Miao, Jianping ; Yuan, Xianglin ; Liu, Jihong ; Liu, Bo</creatorcontrib><description>Prostate cancer (PCa) is one of the most deadly urinary tumors in men globally, and the 5‐year over survival is poor due to metastasis of tumor. It is significant to explore potential biomarkers for early diagnosis and personalized therapy of PCa. In the present study, we performed an integrated analysis based on multiple microarrays in the Gene Expression Omnibus (GEO) dataset and obtained differentially expressed genes (DEGs) between 510 PCa and 259 benign issues. The weighted correlation network analysis indicated that prognostic profile was the most relevant to DEGs. Then, univariate and multivariate COX regression analyses were conducted and four prognostic genes were obtained to establish a four‐gene prognostic model. And the predictive effect and expression profiles of the four genes were well validated in another GEO dataset, The Cancer Genome Atlas and the Human Protein Atlas datasets. Furthermore, combination of four‐gene model and clinical features was analyzed systematically to guide the prognosis of patients with PCa to a largest extent. In summary, our findings indicate that four genes had important prognostic significance in PCa and combination of four‐gene model and clinical features could achieve a better prediction to guide the prognosis of patients with PCa.
Prostate cancer (PCa) is one of the most deadly urinary tumors in men globally, and the progression and development of PCa is associated with copious genetic aberrations. This study is aimed to add novel biomarkers of PCa development and prognosis by analyzing the genetic changes and clinical traits comprehensively. Based on integrated analysis, four genes were significantly related to the prognosis of PCa and well validated in other datasets. Furthermore, combination of four genes and clinical features achieved a better prediction to guide the prognosis of patients with PCa.</description><identifier>ISSN: 2045-7634</identifier><identifier>EISSN: 2045-7634</identifier><identifier>DOI: 10.1002/cam4.3453</identifier><identifier>PMID: 32924329</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>3-Oxo-5-alpha-Steroid 4-Dehydrogenase - genetics ; Androgen-Binding Protein - genetics ; Biomarkers ; Biomarkers, Tumor - genetics ; Cancer Biology ; Case-Control Studies ; clinical features ; Databases, Genetic ; Datasets ; DNA microarrays ; Enhancer of Zeste Homolog 2 Protein - genetics ; four‐gene signature ; Gene expression ; Genomes ; Humans ; Kaplan-Meier Estimate ; Male ; Medical prognosis ; Membrane Proteins - genetics ; Metastases ; Mortality ; Neoplasm Grading ; Neoplasm Staging ; Ontology ; Original Research ; Prognosis ; Proportional Hazards Models ; Prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - genetics ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Proteins ; Risk Factors ; ROC Curve ; Survival Rate ; Transcriptome ; Tumors</subject><ispartof>Cancer medicine (Malden, MA), 2020-11, Vol.9 (21), p.8202-8215</ispartof><rights>2020 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5093-5ef8495c14f52c0090b4daa8a6a1cacbc9cbda33a2179503ab76ced8f3bca8e23</citedby><cites>FETCH-LOGICAL-c5093-5ef8495c14f52c0090b4daa8a6a1cacbc9cbda33a2179503ab76ced8f3bca8e23</cites><orcidid>0000-0001-5118-1890</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2457569181/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2457569181?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,37013,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32924329$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yuan, Penghui</creatorcontrib><creatorcontrib>Ling, Le</creatorcontrib><creatorcontrib>Fan, Qing</creatorcontrib><creatorcontrib>Gao, Xintao</creatorcontrib><creatorcontrib>Sun, Taotao</creatorcontrib><creatorcontrib>Miao, Jianping</creatorcontrib><creatorcontrib>Yuan, Xianglin</creatorcontrib><creatorcontrib>Liu, Jihong</creatorcontrib><creatorcontrib>Liu, Bo</creatorcontrib><title>A four‐gene signature associated with clinical features can better predict prognosis in prostate cancer</title><title>Cancer medicine (Malden, MA)</title><addtitle>Cancer Med</addtitle><description>Prostate cancer (PCa) is one of the most deadly urinary tumors in men globally, and the 5‐year over survival is poor due to metastasis of tumor. It is significant to explore potential biomarkers for early diagnosis and personalized therapy of PCa. In the present study, we performed an integrated analysis based on multiple microarrays in the Gene Expression Omnibus (GEO) dataset and obtained differentially expressed genes (DEGs) between 510 PCa and 259 benign issues. The weighted correlation network analysis indicated that prognostic profile was the most relevant to DEGs. Then, univariate and multivariate COX regression analyses were conducted and four prognostic genes were obtained to establish a four‐gene prognostic model. And the predictive effect and expression profiles of the four genes were well validated in another GEO dataset, The Cancer Genome Atlas and the Human Protein Atlas datasets. Furthermore, combination of four‐gene model and clinical features was analyzed systematically to guide the prognosis of patients with PCa to a largest extent. In summary, our findings indicate that four genes had important prognostic significance in PCa and combination of four‐gene model and clinical features could achieve a better prediction to guide the prognosis of patients with PCa.
Prostate cancer (PCa) is one of the most deadly urinary tumors in men globally, and the progression and development of PCa is associated with copious genetic aberrations. This study is aimed to add novel biomarkers of PCa development and prognosis by analyzing the genetic changes and clinical traits comprehensively. Based on integrated analysis, four genes were significantly related to the prognosis of PCa and well validated in other datasets. Furthermore, combination of four genes and clinical features achieved a better prediction to guide the prognosis of patients with PCa.</description><subject>3-Oxo-5-alpha-Steroid 4-Dehydrogenase - genetics</subject><subject>Androgen-Binding Protein - genetics</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Cancer Biology</subject><subject>Case-Control Studies</subject><subject>clinical features</subject><subject>Databases, Genetic</subject><subject>Datasets</subject><subject>DNA microarrays</subject><subject>Enhancer of Zeste Homolog 2 Protein - genetics</subject><subject>four‐gene signature</subject><subject>Gene expression</subject><subject>Genomes</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Membrane Proteins - genetics</subject><subject>Metastases</subject><subject>Mortality</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Ontology</subject><subject>Original Research</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - genetics</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Proteins</subject><subject>Risk Factors</subject><subject>ROC Curve</subject><subject>Survival Rate</subject><subject>Transcriptome</subject><subject>Tumors</subject><issn>2045-7634</issn><issn>2045-7634</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1ks1q3DAQgE1paUKaQ1-gCHppD5vo3_KlsCz9CaT00p7FeDx2tHjtreRtyK2PkGfMk1TeTUNSqA4a_Xx8DDNTFK8FPxOcy3OEjT5T2qhnxbHk2ixKq_TzR-ej4jSlNc-r5NKW4mVxpGQldd6Oi7Bk7biLd79vOxqIpdANMO0iMUhpxAATNew6TFcM-zAEhJ61tAcSQxhYTdNEkW0jNQGnHMduGFNILAzzJU1ZMINI8VXxooU-0el9PCl-fPr4ffVlcfnt88VqeblAwyu1MNQ6XRkUujUSOa94rRsABxYEAtZYYd2AUiBFWRmuoC4tUuNaVSM4kuqkuDh4mxHWfhvDBuKNHyH4_cMYOw9xCtiTrziUdVOicy1qp0swuY5SWEc1NAQ2uz4cXNtdvaEGaZgi9E-kT3-GcOW78ZcvrVZWz8m8uxfE8eeO0uQ3ISH1PQw07pKXWktTWeNMRt_-g65zY4ZcqkyZ0thKOJGp9wcKc3VTpPYhGcH9PA9-ngc_z0Nm3zzO_oH82_0MnB-A69DTzf9NfrX8qvfKP8JOwk4</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Yuan, Penghui</creator><creator>Ling, Le</creator><creator>Fan, Qing</creator><creator>Gao, Xintao</creator><creator>Sun, Taotao</creator><creator>Miao, Jianping</creator><creator>Yuan, Xianglin</creator><creator>Liu, Jihong</creator><creator>Liu, Bo</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5118-1890</orcidid></search><sort><creationdate>202011</creationdate><title>A four‐gene signature associated with clinical features can better predict prognosis in prostate cancer</title><author>Yuan, Penghui ; Ling, Le ; Fan, Qing ; Gao, Xintao ; Sun, Taotao ; Miao, Jianping ; Yuan, Xianglin ; Liu, Jihong ; Liu, Bo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5093-5ef8495c14f52c0090b4daa8a6a1cacbc9cbda33a2179503ab76ced8f3bca8e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>3-Oxo-5-alpha-Steroid 4-Dehydrogenase - genetics</topic><topic>Androgen-Binding Protein - genetics</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Cancer Biology</topic><topic>Case-Control Studies</topic><topic>clinical features</topic><topic>Databases, Genetic</topic><topic>Datasets</topic><topic>DNA microarrays</topic><topic>Enhancer of Zeste Homolog 2 Protein - genetics</topic><topic>four‐gene signature</topic><topic>Gene expression</topic><topic>Genomes</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Membrane Proteins - genetics</topic><topic>Metastases</topic><topic>Mortality</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Ontology</topic><topic>Original Research</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - genetics</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Proteins</topic><topic>Risk Factors</topic><topic>ROC Curve</topic><topic>Survival Rate</topic><topic>Transcriptome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yuan, Penghui</creatorcontrib><creatorcontrib>Ling, Le</creatorcontrib><creatorcontrib>Fan, Qing</creatorcontrib><creatorcontrib>Gao, Xintao</creatorcontrib><creatorcontrib>Sun, Taotao</creatorcontrib><creatorcontrib>Miao, Jianping</creatorcontrib><creatorcontrib>Yuan, Xianglin</creatorcontrib><creatorcontrib>Liu, Jihong</creatorcontrib><creatorcontrib>Liu, Bo</creatorcontrib><collection>Wiley Open Access</collection><collection>Wiley-Blackwell Free Backfiles(OpenAccess)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Biological Science Journals</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cancer medicine (Malden, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yuan, Penghui</au><au>Ling, Le</au><au>Fan, Qing</au><au>Gao, Xintao</au><au>Sun, Taotao</au><au>Miao, Jianping</au><au>Yuan, Xianglin</au><au>Liu, Jihong</au><au>Liu, Bo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A four‐gene signature associated with clinical features can better predict prognosis in prostate cancer</atitle><jtitle>Cancer medicine (Malden, MA)</jtitle><addtitle>Cancer Med</addtitle><date>2020-11</date><risdate>2020</risdate><volume>9</volume><issue>21</issue><spage>8202</spage><epage>8215</epage><pages>8202-8215</pages><issn>2045-7634</issn><eissn>2045-7634</eissn><abstract>Prostate cancer (PCa) is one of the most deadly urinary tumors in men globally, and the 5‐year over survival is poor due to metastasis of tumor. It is significant to explore potential biomarkers for early diagnosis and personalized therapy of PCa. In the present study, we performed an integrated analysis based on multiple microarrays in the Gene Expression Omnibus (GEO) dataset and obtained differentially expressed genes (DEGs) between 510 PCa and 259 benign issues. The weighted correlation network analysis indicated that prognostic profile was the most relevant to DEGs. Then, univariate and multivariate COX regression analyses were conducted and four prognostic genes were obtained to establish a four‐gene prognostic model. And the predictive effect and expression profiles of the four genes were well validated in another GEO dataset, The Cancer Genome Atlas and the Human Protein Atlas datasets. Furthermore, combination of four‐gene model and clinical features was analyzed systematically to guide the prognosis of patients with PCa to a largest extent. In summary, our findings indicate that four genes had important prognostic significance in PCa and combination of four‐gene model and clinical features could achieve a better prediction to guide the prognosis of patients with PCa.
Prostate cancer (PCa) is one of the most deadly urinary tumors in men globally, and the progression and development of PCa is associated with copious genetic aberrations. This study is aimed to add novel biomarkers of PCa development and prognosis by analyzing the genetic changes and clinical traits comprehensively. Based on integrated analysis, four genes were significantly related to the prognosis of PCa and well validated in other datasets. Furthermore, combination of four genes and clinical features achieved a better prediction to guide the prognosis of patients with PCa.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>32924329</pmid><doi>10.1002/cam4.3453</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-5118-1890</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2045-7634 |
ispartof | Cancer medicine (Malden, MA), 2020-11, Vol.9 (21), p.8202-8215 |
issn | 2045-7634 2045-7634 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_90a7bd7c88fc4847a53452168ebadea6 |
source | Open Access: PubMed Central; Publicly Available Content Database; Wiley Open Access |
subjects | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - genetics Androgen-Binding Protein - genetics Biomarkers Biomarkers, Tumor - genetics Cancer Biology Case-Control Studies clinical features Databases, Genetic Datasets DNA microarrays Enhancer of Zeste Homolog 2 Protein - genetics four‐gene signature Gene expression Genomes Humans Kaplan-Meier Estimate Male Medical prognosis Membrane Proteins - genetics Metastases Mortality Neoplasm Grading Neoplasm Staging Ontology Original Research Prognosis Proportional Hazards Models Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - genetics Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Proteins Risk Factors ROC Curve Survival Rate Transcriptome Tumors |
title | A four‐gene signature associated with clinical features can better predict prognosis in prostate cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T06%3A21%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20four%E2%80%90gene%20signature%20associated%20with%20clinical%20features%20can%20better%20predict%20prognosis%20in%20prostate%20cancer&rft.jtitle=Cancer%20medicine%20(Malden,%20MA)&rft.au=Yuan,%20Penghui&rft.date=2020-11&rft.volume=9&rft.issue=21&rft.spage=8202&rft.epage=8215&rft.pages=8202-8215&rft.issn=2045-7634&rft.eissn=2045-7634&rft_id=info:doi/10.1002/cam4.3453&rft_dat=%3Cproquest_doaj_%3E2442596585%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5093-5ef8495c14f52c0090b4daa8a6a1cacbc9cbda33a2179503ab76ced8f3bca8e23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2457569181&rft_id=info:pmid/32924329&rfr_iscdi=true |